ACT-AKI: A Randomized, Multicenter, Double-Blind,
Placebo-Controlled Study of AC607 for the Treatment of Acute Kidney
Injury in Cardiac Surgery Subjects
PI: Francis Ferdinand, MD
CRC: Susan Herring, RN - 484.476.8514
To evaluate an investigational agent administered to patients post
on-pump cardiac surgery who develop AKI. On-Pump cardiac surgery
patients who have an elevation in Creatinine post-up of >0.5mg/dL
from pre-op baseline Creatinine within the first 48 hours after surgery.
BCT197: A two-part, randomized, double-blind,
placebo-controlled, single dose study of BCT197 for the prevention of
acute kidney injury (AKI) in patients undergoing elective cardiac
surgery with cardiopulmonary bypass
PI: Scott Goldman, MD
CR: Susan Herring, RN - 484.476.8514
To evaluate if a single dose of a novel new agent will reduce Acute
Kidney Injury during cardiac surgery. Patients age 40 to 85 years and
scheduled for elective cardiac surgery with cardiopulmonary bypass
(CABG, AVR, MVR - repair or replacement)
For additional information on cardiovascular clinical
trials, please call Ann Marie Chikowski, BSN, RN, CCRC, Clinical
Research Manager at 484.476.3030.
For more information, call 1.866.CALL.MLH.